Brii Biosciences (FRA:7SS) Interest Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7SS Brii Biosciences Ltd FRA:7SS
33 GF Score
Price €0.09
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:7SS
33GF Score
Brii Biosciences Ltd FRA:7SS
Interest Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences Business Description

Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a clinical-stage biotechnology company headquartered in China with operations in the United States. It develops therapies for infectious diseases and central nervous system conditions with significant public health burdens, particularly in China. Its pipeline targets hepatitis B virus, HIV, multidrug-resistant and extensively drug-resistant gram-negative infections, and depression and other mental health disorders. The company advances both internally discovered candidates and in-licensed assets, often through collaborations with multinational pharmaceutical partners, and conducts clinical trials in China and other markets. As a pre-commercial biopharmaceutical company, Brii Biosciences has historically generated limited product revenue, relying instead on equity financing, partnership milestones, and licensing arrangements to fund research and development. Its strategy centers on bringing differentiated therapies to underserved patient populations in China and globally.
33GF Score

Get the complete analysis for FRA:7SS

Interest Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price